Recent Analysts’ Ratings Updates for Madrigal Pharmaceuticals (MDGL)

Several brokerages have updated their recommendations and price targets on shares of Madrigal Pharmaceuticals (NASDAQ: MDGL) in the last few weeks:

• 7/29/2026 – Madrigal Pharmaceuticals was given a new $587.00 price target by Canaccord Genuity Group Inc..
• 7/27/2026 – Madrigal Pharmaceuticals is now covered by Wells Fargo & Company. They set an “overweight” rating and a $685.00 price target on the stock.
• 7/27/2026 – Madrigal Pharmaceuticals is now covered by Wells Fargo & Company. They set an “overweight” rating and a $685.00 price target on the stock.
• 7/17/2026 – Madrigal Pharmaceuticals had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 7/17/2026 – Madrigal Pharmaceuticals had its “outperform” rating reaffirmed by Citigroup Inc..
• 6/24/2026 – Madrigal Pharmaceuticals had its “overweight” rating reaffirmed by Piper Sandler.
• 6/11/2026 – Madrigal Pharmaceuticals had its price target lowered by Bank of America Corporation from $550.00 to $542.00. They now have a “neutral” rating on the stock.
• 6/1/2026 – Madrigal Pharmaceuticals was upgraded by Wells Fargo & Company to “overweight”.
• 6/1/2026 – Madrigal Pharmaceuticals had its “market outperform” rating reaffirmed by Citigroup Inc..

Insider Activity

In related news, Director Richard S. Levy sold 5,682 shares of the company’s stock in a transaction dated Friday, May 22nd. The stock was sold at an average price of $515.44, for a total value of $2,928,730.08. Following the completion of the sale, the director owned 22,015 shares in the company, valued at approximately $11,347,411.60. This represents a 20.51% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider David Soergel sold 1,042 shares of the firm’s stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $495.74, for a total value of $516,561.08. Following the transaction, the insider owned 10,033 shares in the company, valued at approximately $4,973,759.42. This trade represents a 9.41% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 7,568 shares of company stock valued at $3,880,711 over the last three months. Company insiders own 17.60% of the company’s stock.

Madrigal Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the development of innovative therapies for cardiovascular, metabolic and liver diseases. The company’s pipeline centers on novel, liver-directed agents designed to address significant unmet medical needs, with an emphasis on nonalcoholic steatohepatitis (NASH) and related metabolic disorders.

The lead product candidate, resmetirom (MGL-3196), is an orally administered, selective thyroid hormone receptor-? agonist in Phase 3 development for the treatment of NASH.